Cannabis Law Report

JANUARY 30, 2019

To expand the number of manufacturers, the Drug Enforcement Administration (DEA) submitted a notice in the Federal Register on August 11, 2016, soliciting applications for licenses to manufacture marijuana for research purposes. The Food and Drug Administration (FDA) recently approved Epidiolex, whose main active ingredient is CBD.

Research and Development 63

Research and Development CBD DEA Law 63

Canna Law Blog

AUGUST 31, 2023

This means that the country’s top health agency has finally conceded that cannabis has medical value, and isn’t a drug of abuse on par with fentanyl or heroin. As an HHS spokesperson explained: “While HHS’s scientific and medical evaluation is binding on DEA, the scheduling recommendation is not. I could go on.

DEA 128

DEA Marijuana Banking Research and Development 128

Cannabis Law Report

MARCH 25, 2019

The Attorney General forwards the request to the Health and Human Services Secretary and requests a scientific and medical evaluation and recommendation, as specified by 23 USC 811(b-c). HHS, through the Food and Drug Administration, conducts an assessment and returns a recommendation to the Attorney General “in a timely manner.”.

Banking 45

Banking Law Marijuana State Laws 45

Veriheal

NOVEMBER 7, 2024

The Drug Enforcement Administration (DEA) announced in August that a hearing regarding the reclassification decision will take place on December 2, 2024, before an administrative law judge. Then, the DEA will review the report and draft a final ruling, factoring in all relevant information submitted during the public comment period.

DEA 97

DEA Policy Chronic Pain Marijuana 97